Report calls for generic medicines boost

April 12, 2006

Brussels, 11 Apr 2006

A new report from researchers at the Catholic University of Leuven has recommended a strengthening of the generic pharmaceuticals market, which could reduce the costs for EU heath services considerably.

The report, written by Professor Steven Simoens and Sandra De Coster at the Centre for Drug and Patient Information, suggests that if the top ten pharmaceuticals were substituted for generic equivalents, pharmaceutical expenditure would drop by between and 48 per cent, depending on the specific Member State.

Generic medicines are unbranded and will contain identical active ingredients to those in the more familiar branded products. The main differences could be in packaging, value-added components, such as taste, or simply in price - generic medicines are typically 20 to 80 per cent of the cost of the branded equivalents.

While paying less for a medicine with identical active ingredients makes good economic sense, a stronger generic medicine market could also encourage 'originator companies to develop innovative medicines and to reduce prices on off-patent originator medicines, thus generating additional savings to patients'.

In order to achieve these savings, the report urges a coherent EU policy on the use of generic medicines, which varies considerably between Member States. In Germany and the UK, the generic pharmaceutical market is effectively deregulated, with a free pricing policy. The study found this approach to be successful, but in the Netherlands and Denmark, pharmacists drive the generic substitution market, which, coupled with the free pricing policy is more effective again.

In short, the report recommends seven points to boost the generic market: a coherent EU-wide policy governing generic medicines; a free pricing policy; information passed on to both doctors and pharmacists about the differences in price between generic and branded medicines; a confidence boost for the efficacy of generic medicines with doctors; incentives for doctors who prescribe generic medicines; removal of disincentives to do the same; and incentives for patients to demand generics.

The researchers drew their conclusions from a systematic review of the policies and approaches taken throughout Europe. Professor Simoens hopes that the report will 'aid policy makers in gaining a better understanding of how pharmaceutical companies, physicians, pharmacists and patients react to incentives created by generic medicines policy, and [...] propose tools that policy makers can use to continue developing domestic generic medicines retail markets.'

Text of the report

CORDIS RTD-NEWS/© European Communities, 2005
Item source

You've reached your article limit.

Register to continue

Registration is free and only takes a moment. Once registered you can read a total of 3 articles each month, plus:

  • Sign up for the editor's highlights
  • Receive World University Rankings news first
  • Get job alerts, shortlist jobs and save job searches
  • Participate in reader discussions and post comments
Register

Have your say

Log in or register to post comments

Most Commented

Worried man wiping forehead
Two academics explain how to beat some of the typical anxieties associated with a doctoral degree

Felipe Fernández-Armesto takes issue with a claim that the EU has been playing the sovereignty card in Brexit negotiations

John McEnroe arguing with umpire. Tennis

Robert MacIntosh and Kevin O’Gorman explain how to negotiate your annual performance and development review

Man throwing axes

UCU attacks plans to cut 171 posts, but university denies Brexit 'the reason'

Cricket player and umpire exchanging bribe

The need to accommodate foreign students undermines domestic practices, says Lincoln Allison, spying parallels between UK universities and global sports bodies such as Fifa